Septic
cardiomyopathy is a life-threatening complication of
severe sepsis and
septic shock. Oxidative stress and
mitochondrial dysfunction have been identified as significant abnormalities in septic
cardiomyopathy. However, specific treatments are rare. This study aims to investigate the impact of β-hydroxybutyrate (β-OHB) on septic
cardiomyopathy and explore the underlying mechanism(s). We found that pretreatment of D-β-hydroxybutyrate-(R)-1,3 butanediol monoester (
ketone ester, 3 mg/g
body weight, once daily) by gavage for three days elevated the levels of
ketone bodies, especially that of β-hydroxybutyrate (β-OHB) in the circulation and mouse hearts, which exerted a protective effect against
lipopolysaccharide (LPS, 20 mg/kg)-induced septic
cardiomyopathy in mice. In addition, an LPS-stimulated macrophage-
conditioned medium (MCM) was used to mimic the pathological process of septic
cardiomyopathy. Mechanistically, β-OHB alleviated myocardial oxidative stress and improved mitochondrial respiratory function through the
antioxidant FoxO3a/MT2 pathway activated via
histone deacetylase (HDAC) inhibition, which ultimately enhanced heart performance in septic
cardiomyopathy. Our results, therefore, suggested an unappreciated critical role of β-OHB in septic heart protection as well as highlighted the potential of β-OHB as a simple remedy for the septic
cardiomyopathy population.